Its not a one-size-fits-all approach and multiple sessions may be required to achieve the desired results
New combinations and oral GLP-1 options The field of GLP-1 therapies is rapidly evolving, with exciting developments that enhance convenience and efficacy
Some patients at maintenance doses with lower-concentration vials need to split their dose across two injections

Cash Pay Options Manufacturer Direct Programs: Novo Nordisk: $199/month for first two doses, then $349/month Eli Lilly LillyDirect: $299-$499/month depending on dose TrumpRx Platform (Launching Early 2026): Injectable GLP-1s: $350/month initially, dropping to $250 within 2 years Oral GLP-1s (pending FDA approval): $149/month for starting doses GoodRx/Discount Cards: Prices vary by pharmacy and location Typically $900-$1,200/month without manufacturer programs Check current prices at your local Hinsdale pharmacies Cost Comparison: What You'll Actually Pay Ozempic (semaglutide for diabetes): Insurance copay: $25-$100/month Medicare (2026): $50/month Cash (manufacturer direct): $199-$349/month List price: $969/month Wegovy (semaglutide for obesity): Insurance copay: Often not covered Medicare (2026): $50/month Cash (manufacturer direct): $199-$349/month List price: $1,349/month Mounjaro (tirzepatide for diabetes): Insurance copay: $25-$100/month Medicare (2026): $50/month List price: $1,069/month Zepbound (tirzepatide for obesity): Insurance copay: Often not covered Medicare (2026): $50/month Cash (manufacturer direct): $299-$499/month List price: $1,059/month At Well Endocrinology, we help patients navigate insurance coverage, prior authorizations, and manufacturer savings programs to minimize out-of-pocket costs

Earlier in the year, Novos semaglutide-based GLP-1 drugs (including Ozempic and Wegovy) were listed among the drugs subject to Medicare pricing negotiations, with the negotiated price dropping 71% for Medicare beneficiaries, set to take effect in 2027